Fungicidal versus Fungistatic: what's in a word? (Q37123394)

18 August 2017

1 reference

title

Fungicidal versus Fungistatic: what's in a word? (English)

1 reference

18 August 2017

James S Lewis

1

1 reference

PubMed ID

18377336

18 August 2017

John R Graybill

series ordinal

2

1 reference

PubMed ID

18377336

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

6

1 reference

18 August 2017

927-935

1 reference

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

18 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Potential fungicidal effect of voriconazole against Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Interactions between triazoles and amphotericin B against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Toward more effective antifungal therapy: the prospects of combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Micafungin: a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.6.927

21 January 2018

Identifiers

DOI

10.1517/14656566.9.6.927

1 reference

18 August 2017

1 reference

PubMed ID

18377336